Bone diseases are often a result of increased numbers of osteoclasts, or bone-resorbing
cells. Bone metastases are a significant cause of morbidity in many types of cancer. An …

Purpose The goal of this study was to determine the specificity of 64 Cu-CB-TE2A-c
(RGDyK)(64 Cu-RGD) for osteoclast-related diseases, such as Paget's disease or …

This article describes the evaluation of the radiopharmaceutical 64Cu-CB-TE2A-c
(RGDyK)(64Cu-RGD) as an imaging agent for osteolytic bone metastases and their …

Objective To investigate the value of integrin α v β 3 targeted imaging with 99m Tc-HYNIC-
PEG 4-E [PEG 4-c (RGDfk)] 2 (99m Tc-3P-RGD 2) as a radiotracer in dectecting osteolytic …

68Ga (T 1/2= 68 min, a generator-produced nuclide) has great potential as a radionuclide
for clinical positron emission tomography (PET). Because poly-glutamic and poly-aspartic …

A hybrid compound (DO3A-BP) featuring a radiometal bifunctional chelator (1, 4, 7, 10-
tetraazacyclotetradecane-N, N′, N ″, N‴-tetraacetic acid, DOTA) and an osteoclast …

INTRODUCTION: Based on the concept of bifunctional radiopharmaceuticals, we have
previously developed 186Re-complex-conjugated bisphosphonate analogs for palliation of …

To develop a radiopharmaceutical for the palliation of painful bone metastases based on the
concept of bifunctional radiopharmaceuticals, we synthesized a bisphosphonate derivative …

Abstract 67Ga-DOTA-(L-Asp) 11 and 67Ga-DOTA-(L-Asp) 14, which have been developed
as bone imaging agents, showed a high accumulation in bone and a rapid blood clearance …

Peptide receptor-targeted radionuclide therapy is nowadays also being performed with
DOTA-conjugated peptides, such as [DOTA 0, Tyr 3] octreotate, labelled with radionuclides …